MYBPC3 polymorphism is a modifier for expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy
Authors:
- 8 April 2005
- journal article
- clinical trial
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 329 (2) , 796-799
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Molecular genetics of familial hypertrophic cardiomyopathy (FHC)Journal of Human Genetics, 2003
- A high risk phenotype of hypertrophic cardiomyopathy associated with a compound genotype of two mutated β-myosin heavy chain genesHuman Genetics, 1998
- CorrespondenceCardiovascular Research, 1997
- A Signaling Pathway to Translational ControlCell, 1996
- A Molecular Map of the Interactions between Titin and Myosin‐Binding Protein CEuropean Journal of Biochemistry, 1996
- The anatomy of a molecular giant: How the sarcomere cytoskeleton is assembled from immunoglobulin superfamily moleculesJournal of Molecular and Cellular Cardiology, 1995
- Association between a Deletion Polymorphism of the Angiotensin-Converting-Enzyme Gene and Left Ventricular HypertrophyNew England Journal of Medicine, 1994
- Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain geneJACC, 1993
- Left ventricular hypertrophy: Effect on survivalJACC, 1993
- Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart StudyNew England Journal of Medicine, 1990